Company Description
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies.
The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.
It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization.
The company was founded in 2011 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 1997 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Matthew Franklin M.B.A. |
Contact Details
Address: 71 Commercial Street, Mailbox 312 Boston, Massachusetts 02109 United States | |
| Phone | 617-456-0597 |
| Website | akiliinteractive.com |
Stock Details
| Ticker Symbol | AKLI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850266 |
| ISIN Number | US00974B1070 |
| Employer ID | 92-3654772 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Walter Edward Martucci II, Ph.D. | Co-Founder and Chairman |
| Matthew Franklin M.B.A. | President, Chief Executive Officer and Director |
| Dr. Adam Gazzaley M.D., Ph.D. | Co-Founder, Chief Science Advisor and Director |
| Jacqueline L. Studer J.D. | Chief Legal Officer, General Counsel and Secretary |
| Caty Reid | Vice President of Marketing and Communications |
| Dr. Scott H. Kollins Ph.D. | Chief Medical Officer |
| Jonathan David | Chief Product Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 8-K | Current Report |
| Mar 6, 2024 | ARS | Filing |
| Mar 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 6, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 23, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 21, 2024 | 8-K | Current Report |